Manipal Health board approves Q1FY27 unaudited standalone, consolidated results
- Revenue grew 38.1% YoY to ₹3,091 crore in Q1FY27
- Board approved unaudited standalone and consolidated results on August 20, 2026
- Adjusted PAT grew 30.9% YoY after excluding acquisition-related interest costs
- Occupancy rates improved by 290 bps to 65.0%
- CONGO-R specialty gross inpatient revenue grew 45% YoY

*this image is generated using AI for illustrative purposes only.
Manipal Health Enterprises reported a 38.1% year-on-year revenue increase to ₹3,091 crore for the quarter ended June 30, 2026. The Board of Directors approved the unaudited standalone and consolidated financial results at its meeting held on August 20, 2026. The results were published in Business Standard and Vishwavani on August 21, 2026.
The pan-India hospital chain delivered strong operational metrics as it absorbed capacity from its recent Sahyadri acquisition. The financial statements were based on the recommendation of the Audit Committee. BSR & Co. LLP served as the statutory auditors, issuing a limited review report on the figures.
The company posted an EBITDA of ₹749 crore, reflecting a 26.4% year-on-year growth. However, the EBITDA margin contracted to 23.8% in Q1FY27 from 26.2% in the prior year period. Excluding a one-off gain of ₹15 crore recorded in the prior year period, adjusted EBITDA growth stood at 29.7%. Profit after tax (PAT) was reported at ₹243 crore. However, excluding ₹89 crore in post-tax interest on non-convertible debentures raised for the Sahyadri acquisition, adjusted PAT grew 30.9% year-on-year.
Operational Metrics
Patient volumes drove the top-line expansion. Inpatient volumes rose 38.8% year-on-year, while outpatient volumes increased by 26.0%. Occupancy rates improved by 290 basis points to 65.0%, indicating effective utilization of the expanded network. Average Revenue Per Occupied Bed (ARPOB), excluding the Sahyadri portfolio, grew 8.7% year-on-year to ₹77,200 per day, signaling improved revenue intensity across the existing legacy network.
| Metric | Q1 FY27 | Q1 FY26 | YoY Change |
|---|---|---|---|
| Revenue | ₹3,091 crore | ₹2,238 crore | +38.1% |
| EBITDA | ₹749 crore | ₹593 crore | +26.4% |
| EBITDA Margin | 23.8% | 26.2% | -240 bps |
| PAT | ₹243 crore | ₹254 crore | -4.2% |
| Adjusted PAT | ₹332 crore | ₹254 crore | +30.9% |
What the Numbers Show
Reported PAT declined 4.2% year-on-year to ₹243 crore, contrasting sharply with the 38.1% revenue growth. This divergence is attributable to the ₹89 crore post-tax interest expense on debt raised for the Sahyadri acquisition. When this financing cost is excluded, underlying profitability grew 30.9%, demonstrating that the core operational performance outpaced the drag from acquisition-related leverage. Additionally, while revenue grew significantly, the EBITDA margin contracted by 240 basis points to 23.8%, reflecting the integration costs and lower-margin mix associated with the new capacity.
Sahyadri Integration
Sahyadri Hospitals contributed significantly to the quarter's performance, recording 12.8% revenue growth and 18.7% EBITDA growth year-on-year based on erstwhile management reporting. The integration has progressed across clinical and operational functions, with centralized procurement pricing and co-branding initiatives already implemented. Sahyadri's ARPOB improved by 14.7% year-on-year to ₹44,800 per day.
Specialty Mix
High-acuity specialties continued to drive momentum within the network. Gross inpatient revenue from CONGO-R specialties (Cardiac, Oncology, Neuro, Gastro, Ortho, Renal) grew 45% year-on-year. Oncology and Orthopedics were key contributors, with inpatient revenue growth of 62% and 49% respectively. The specialty mix for these high-value procedures increased to 65.4% of total gross inpatient revenue.
Historical Stock Returns for Manipal Health Enterprises
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.45% | +3.29% | +8.16% | 0.0% | 0.0% | 0.0% |
How long is Manipal Health Enterprises expected to carry the ₹89 crore quarterly interest burden from the Sahyadri acquisition before achieving debt amortization or refinancing?
What specific operational synergies or cost-cutting measures are planned to reverse the 240 basis point contraction in EBITDA margins in the coming quarters?
Will the significant growth in high-acuity CONGO-R specialties (particularly Oncology and Orthopedics) continue to drive ARPOB expansion, or will volume growth eventually outpace price increases?
































